Ketamine-inspired nasal spray for depression on cusp of landmark FDA approval

A new nasal spray for depression, utilizing a novel drug called esketamine, has passed the last step on its way to final FDA approval. An advisory panel to the Food and Drug Administration (FDA) voted in favor of the new drug’s risk/benefit profile meaning the ketamine-inspired treatment may be finally approved for clinical use within the next month.

Originally developed decades ago as a novel anesthetic, ketamine has been undergoing a renaissance in recent years. Many scientists are suggesting this drug exerts a unique action on the brain and can result in stark and rapid anti-depressant effects. As the drug is already approved for clinical use in the United States, “ketamine clinics” have been popping up across the country, administering the drug to patients for a variety of off-label uses.

Of course in the world of Big Pharma there is no money to be made investing in clinical trials for a decades-old drug past its patent. So in comes esketamine, a chemical cousin of ketamine with many similar pharmacological actions. Esketamine is roughly twice as strong as ketamine, eliminated by the body faster, and allegedly presents less negative dissociative symptoms when compared to its relative. For the most part, esketamine acts on the brain in similar ways to ketamine, except it doesn’t influence a few key neurological receptors.

Read from original article

Schedule a Call

Entheogen-assisted Healing

Taking entheogens can be like air travel: people do it all the time, it’s usually fine, but when it’s not fine, it’s sometimes very bad. We’ve been there. And that’s where an experienced GUIDE can make the difference in the outcome.
I’m available by phone if you or someone you know wants to ask questions of ANY nature. Use this link to schedule a call HERE.